The Inhibitors of Histone Deacetylase Suberoylanilide Hydroxamate and Trichostatin A Release Nitric Oxide Upon Oxidation

Overview

Journal Free Radic Biol Med

Specialties Biochemistry
Biology
General Medicine

Date 2009 May 19

PMID 19447172

Citations 9

Authors

Yuval Samuni

Wilmarie Flores-Santana

Murali C Krishna

James B Mitchell

David A Wink

Affiliations

Soon will be listed here.

Abstract

Suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza) is the lead compound of a new class of histone deacetylase (HDAC) inhibitors used as anticancer drugs that have been shown to affect multiple proteins associated with gene expression, cell proliferation, and migration. Studies have also demonstrated the essential role of the hydroxamate moiety of SAHA in HDAC inhibition. The ability of SAHA and its structural analog trichostatin A (TSA) to generate NO upon oxidation was tested directly, by spin trapping of NO using electron paramagnetic resonance spectroscopy, and also indirectly, via the determination of nitrite using the Griess assay. H2O2/metmyoglobin was used to oxidize SAHA and TSA. These studies demonstrate, for the first time, the release of NO from SAHA and its structural analog TSA. We tested the protective effects of SAHA, TSA, and valproic acid (VPA) in mammalian Chinese hamster V79 cells exposed to a bolus of H2O2 for 1 h and monitored the clonogenic cell survival. Both SAHA and TSA afforded significant cytoprotection when co-incubated with H2O2, whereas VPA was ineffective. These studies provide evidence for the release of NO by hydroxamate-containing HDAC inhibitors and their antioxidant effects. Such roles may be an added advantage of this class of HDAC agents used for epigenetic therapies in cancer.

Citing Articles

Deferoxamine produces nitric oxide under ferricyanide oxidation, blood incubation, and UV-irradiation.

Mukosera G, Liu T, Manaen M, Zhu L, Power G, Schroeder H Free Radic Biol Med. 2020; 160:458-470.

PMID: 32828952 PMC: 11059783. DOI: 10.1016/j.freeradbiomed.2020.08.004.

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure.

Qiu X, Rong X, Yang J, Lu Y BMC Ophthalmol. 2019; 19(1):42.

PMID: 30717701 PMC: 6360693. DOI: 10.1186/s12886-019-1056-7.

The effect of metalloprotein inhibitors on cellular metal ion content and distribution.

Chen Y, Lai B, Zhang Z, Cohen S Metallomics. 2017; 9(3):250-257.

PMID: 28168254 PMC: 5362324. DOI: 10.1039/c6mt00267f.

A network pharmacology approach reveals new candidate caloric restriction mimetics in C. elegans.

Calvert S, Tacutu R, Sharifi S, Teixeira R, Ghosh P, de Magalhaes J Aging Cell. 2015; 15(2):256-66.

PMID: 26676933 PMC: 4783339. DOI: 10.1111/acel.12432.

Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide.

Samuni Y, Wink D, Krishna M, Mitchell J, Goldstein S Free Radic Biol Med. 2014; 73:291-8.

PMID: 24880052 PMC: 7670884. DOI: 10.1016/j.freeradbiomed.2014.05.019.

References

Kelman D, DeGray J, Mason R . Reaction of myoglobin with hydrogen peroxide forms a peroxyl radical which oxidizes substrates. J Biol Chem. 1994; 269(10):7458-63. View

Bobko A, Bagryanskaya E, Reznikov V, Kolosova N, Clanton T, Khramtsov V . Redox-sensitive mechanism of no scavenging by nitronyl nitroxides. Free Radic Biol Med. 2004; 36(2):248-58. DOI: 10.1016/j.freeradbiomed.2003.10.022. View

Green L, Wagner D, Glogowski J, Skipper P, Wishnok J, Tannenbaum S . Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982; 126(1):131-8. DOI: 10.1016/0003-2697(82)90118-x. View

Finnin M, Donigian J, Cohen A, Richon V, Rifkind R, Marks P . Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999; 401(6749):188-93. DOI: 10.1038/43710. View

Taira J, Misik V, Riesz P . Nitric oxide formation from hydroxylamine by myoglobin and hydrogen peroxide. Biochim Biophys Acta. 1997; 1336(3):502-8. DOI: 10.1016/s0304-4165(97)00064-0. View

Burkitt M, Raafat A . Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood. 2005; 107(6):2219-22. DOI: 10.1182/blood-2005-08-3429. View

Krishna M, Samuni A, Taira J, Goldstein S, Mitchell J, Russo A . Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and mechanism. J Biol Chem. 1996; 271(42):26018-25. DOI: 10.1074/jbc.271.42.26018. View

Yoshida M, Kijima M, Akita M, Beppu T . Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990; 265(28):17174-9. View

Mann B, Johnson J, He K, Sridhara R, Abraham S, Booth B . Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007; 13(8):2318-22. DOI: 10.1158/1078-0432.CCR-06-2672. View

10.

Kelly W, Marks P . Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005; 2(3):150-7. DOI: 10.1038/ncponc0106. View

11.

Akaike T, Yoshida M, Miyamoto Y, Sato K, Kohno M, Sasamoto K . Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993; 32(3):827-32. DOI: 10.1021/bi00054a013. View

12.

Gladwin M, Shelhamer J, Ognibene F, Nichols J, Link B, Patel D . Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002; 116(2):436-44. DOI: 10.1046/j.1365-2141.2002.03274.x. View

13.

King S . Mechanisms and novel directions in the biological applications of nitric oxide donors. Free Radic Biol Med. 2004; 37(6):735-6. DOI: 10.1016/j.freeradbiomed.2004.01.013. View

14.

Fukuto J, Hobbs A, Ignarro L . Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: the role of physiological oxidants and relevance to the biological activity of HNO. Biochem Biophys Res Commun. 1993; 196(2):707-13. DOI: 10.1006/bbrc.1993.2307. View

15.

Hobbs A, Fukuto J, Ignarro L . Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci U S A. 1994; 91(23):10992-6. PMC: 45152. DOI: 10.1073/pnas.91.23.10992. View

16.

Liochev S, Fridovich I . Copper,zinc superoxide dismutase as a univalent NO(-) oxidoreductase and as a dichlorofluorescin peroxidase. J Biol Chem. 2001; 276(38):35253-7. DOI: 10.1074/jbc.M104237200. View

17.

Liochev S, Fridovich I . Nitroxyl (NO-): a substrate for superoxide dismutase. Arch Biochem Biophys. 2002; 402(2):166-71. DOI: 10.1016/S0003-9861(02)00074-7. View

18.

Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker J, Randolph S . Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008; 26(5):483-8. DOI: 10.1007/s10637-008-9131-6. View

19.

King S . The nitric oxide producing reactions of hydroxyurea. Curr Med Chem. 2003; 10(6):437-52. DOI: 10.2174/0929867033368213. View

20.

Wink D, Mitchell J . Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998; 25(4-5):434-56. DOI: 10.1016/s0891-5849(98)00092-6. View